TG Therapeutics takes up option on PI3K-Delta inhibitor, TGR-1202

23 September 2014

US development stage company TG Therapeutics (Nasdaq: TGTX) says it has exercised its option to license the global rights to TGR-1202, the company's novel, next generation PI3K-delta inhibitor from privately-held Swiss firm Rhizen Pharmaceuticals.

TG Therapeutics and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture which was worth up to $250 million to the Swiss firm (The Pharma Letter August 17, 2012). Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the Company's license option.

Financial terms of the deal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK